This inventor holds 1 USPTO granted patent. Top assignee: Tianjin Medical University. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Innovations in Diabetes Treatment by Hongquan Duan
Introduction
Hongquan Duan is an accomplished inventor based in Tianjin, China. He has made significant contributions to the field of medical science, particularly in the development of flavone derivatives for treating diabetes. His innovative work has the potential to improve the lives of many individuals suffering from this chronic condition.
Latest Patents
Hongquan Duan holds a patent for "Flavone derivatives and their preparative method and medical use." This patent describes the preparative method of flavone derivatives and their application as medicaments for treating diabetes. The structure of these derivatives is defined by specific chemical formulas, where Rand R can represent various functional groups. The pharmacological tests conducted indicate that these flavone derivatives can significantly enhance glucose consumption in Hep-G2 cells, demonstrating insulin resistance activity. Furthermore, they promote the translocation of glucose transporter 4 in skeletal muscle cells, which is crucial for glucose intake and utilization.
Career Highlights
Hongquan Duan is affiliated with Tianjin Medical University, where he conducts his research and development work. His dedication to advancing medical science is evident through his innovative patent and the potential applications of his research in diabetes treatment.
Collaborations
Some of his notable coworkers include Nan Qin and Ying Chen, who contribute to the collaborative efforts in research and development at Tianjin Medical University.
Conclusion
Hongquan Duan's work in developing flavone derivatives represents a significant advancement in diabetes treatment. His innovative approach and dedication to research hold promise for improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile